Retatrutide Dosage: What Amounts Did the Trials Test?

What do these trial amounts mean for you?

An upset stomach became more common as the test amount rose in Phase 2. Trial teams therefore began low and moved up in steps. This page tells what they did and what happened. It isn't a guide for taking the drug. Retatrutide isn't approved, so no drug label gives a dose.

In Phase 2, people got one weekly shot into fat under the skin. The obesity trial tested 1 mg, 4 mg, 8 mg, and 12 mg. Phase 1b began at 0.5 mg and rose as high as 12 mg. Half the drug left the blood in about six days. That long stay made a weekly shot possible in trials.

The retatrutide half life page explains why the drug stays so long.

Keep this in mind as you read the amounts: doctors watched each person, checked their health, and changed the trial plan when problems arose, which no online vial can offer you.

Which retatrutide dosage amounts did trials test?

These are amounts tested in people ^[1][2][4]. They aren't amounts for personal use.

Phase 1b: This trial followed 72 adults with type 2 diabetes for 12 weeks. Exactly 1 group stayed at 3 mg each week. The report writes the rising groups as 3/6 and 3/6/9/12 mg. Those aren't fractions. In 3/6, staff moved through two amounts. In 3/6/9/12, they moved through four. Trial staff made each change on set dates.

Phase 2 obesity: This trial followed 338 adults for 48 weeks. Separate groups worked toward 1, 4, 8, or 12 mg in a weekly shot under the skin. Each group began with less and moved up over several weeks.

Phase 2 type 2 diabetes: This trial followed 281 adults for 36 weeks. The weekly shot began at 0.5 mg and rose in steps to 12 mg.

In the Phase 2 obesity trial, more drug went with more weight loss. The groups lost 8.7% at 1 mg, 17.3% at 4 mg, 22.8% at 8 mg, and 24.2% at 12 mg. The placebo group lost 2.1% ^[1].

Slow increases were part of each trial. Reviews found that moving up slowly can ease nausea with drugs of this kind ^[7].

Did retatrutide side effects rise with the amount?

Yes. In the Phase 2 obesity trial, stomach trouble rose with the test amount ^[1].

• Nausea rose from about 23% at 1 mg to about 45% at 12 mg.
• Vomiting affected 12–28%.
• Diarrhea affected 12–20%.
• Constipation affected 12–22%.
• Health problems made 3% leave at 1 mg and 18% leave at 12 mg.
• Resting pulse rose more with larger amounts. Near 24 weeks, the rise averaged about 5–7 beats per minute at the top amounts.
• About 8% had a reaction where the shot went in.

No one died or had severe low blood sugar in the Phase 2 work. Most stomach problems were mild to moderate. They often eased for people who stayed.

For outside reports from people using research-marked retatrutide, see Retatrutide effects.

Can you safely mix retatrutide powder?

People often ask how to turn retatrutide powder into a shot. There is no approved way to do that. In Phase 2 and Phase 3, Eli Lilly supplied a ready-made pen or syringe for one use. Strict rules kept the trial drug clean and made each amount the same. People in the trials didn't mix it.

Those trials only tested the ready-made drug as a weekly shot under the skin. No approved recipe, liquid, storage temperature, or mixing rule exists for powder sold outside a trial.

Gray-market retatrutide often comes as powder dried by freezing. Mixing directions for that powder come from users or sellers, not an approved drug label. No drug maker has checked the powder for the right drug, strength, or germs.

Where is retatrutide available now?

Retatrutide isn't sold as an approved drug. A doctor can't write a prescription for it. It remains investigational, with no FDA-approved product for patient use.

There is no retail prescription route; trials and research-labelled sales are different situations:

1. Joining a clinical trial. Clinical-trial access depends on the study's eligibility rules and whether recruitment is open. ClinicalTrials.gov records each study's recruitment status.
2. Gray-market material marked for research. No health agency checks it for the right drug, strength, or germs. No doctor or trial team watches its use.

Telehealth does not create a prescription route for retatrutide.

What could delay when retatrutide is available?

Retatrutide has no announced approval date. It remains under clinical investigation. An approval application needs results from the Phase 3 trials. It also needs full records on safety and drug making. Completing a trial does not establish when a drug will reach patients.

No reliable launch window follows from the trial calendar. Trial completion and regulatory review are separate hurdles. Neither supplies a guarantee of approval. ClinicalTrials.gov lists when the weight, diabetes, and heart trials may end. Those dates can change.